Cargando…
Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study
Objective To determine whether higher cumulative use of benzodiazepines is associated with a higher risk of dementia or more rapid cognitive decline. Design Prospective population based cohort. Setting Integrated healthcare delivery system, Seattle, Washington. Participants 3434 participants aged ≥6...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737849/ https://www.ncbi.nlm.nih.gov/pubmed/26837813 http://dx.doi.org/10.1136/bmj.i90 |
_version_ | 1782413533967810560 |
---|---|
author | Gray, Shelly L Dublin, Sascha Yu, Onchee Walker, Rod Anderson, Melissa Hubbard, Rebecca A Crane, Paul K Larson, Eric B |
author_facet | Gray, Shelly L Dublin, Sascha Yu, Onchee Walker, Rod Anderson, Melissa Hubbard, Rebecca A Crane, Paul K Larson, Eric B |
author_sort | Gray, Shelly L |
collection | PubMed |
description | Objective To determine whether higher cumulative use of benzodiazepines is associated with a higher risk of dementia or more rapid cognitive decline. Design Prospective population based cohort. Setting Integrated healthcare delivery system, Seattle, Washington. Participants 3434 participants aged ≥65 without dementia at study entry. There were two rounds of recruitment (1994-96 and 2000-03) followed by continuous enrollment beginning in 2004. Main outcomes measures The cognitive abilities screening instrument (CASI) was administered every two years to screen for dementia and was used to examine cognitive trajectory. Incident dementia and Alzheimer’s disease were determined with standard diagnostic criteria. Benzodiazepine exposure was defined from computerized pharmacy data and consisted of the total standardized daily doses (TSDDs) dispensed over a 10 year period (a rolling window that moved forward in time during follow-up). The most recent year was excluded because of possible use for prodromal symptoms. Multivariable Cox proportional hazard models were used to examine time varying use of benzodiazepine and dementia risk. Analyses of cognitive trajectory used linear regression models with generalized estimating equations. Results Over a mean follow-up of 7.3 years, 797 participants (23.2%) developed dementia, of whom 637 developed Alzheimer’s disease. For dementia, the adjusted hazard ratios associated with cumulative benzodiazepine use compared with non-use were 1.25 (95% confidence interval 1.03 to 1.51) for 1-30 TSDDs; 1.31 (1.00 to 1.71) for 31-120 TSDDs; and 1.07 (0.82 to 1.39) for ≥121 TSDDs. Results were similar for Alzheimer’s disease. Higher benzodiazepine use was not associated with more rapid cognitive decline. Conclusion The risk of dementia is slightly higher in people with minimal exposure to benzodiazepines but not with the highest level of exposure. These results do not support a causal association between benzodiazepine use and dementia. |
format | Online Article Text |
id | pubmed-4737849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-47378492016-02-09 Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study Gray, Shelly L Dublin, Sascha Yu, Onchee Walker, Rod Anderson, Melissa Hubbard, Rebecca A Crane, Paul K Larson, Eric B BMJ Research Objective To determine whether higher cumulative use of benzodiazepines is associated with a higher risk of dementia or more rapid cognitive decline. Design Prospective population based cohort. Setting Integrated healthcare delivery system, Seattle, Washington. Participants 3434 participants aged ≥65 without dementia at study entry. There were two rounds of recruitment (1994-96 and 2000-03) followed by continuous enrollment beginning in 2004. Main outcomes measures The cognitive abilities screening instrument (CASI) was administered every two years to screen for dementia and was used to examine cognitive trajectory. Incident dementia and Alzheimer’s disease were determined with standard diagnostic criteria. Benzodiazepine exposure was defined from computerized pharmacy data and consisted of the total standardized daily doses (TSDDs) dispensed over a 10 year period (a rolling window that moved forward in time during follow-up). The most recent year was excluded because of possible use for prodromal symptoms. Multivariable Cox proportional hazard models were used to examine time varying use of benzodiazepine and dementia risk. Analyses of cognitive trajectory used linear regression models with generalized estimating equations. Results Over a mean follow-up of 7.3 years, 797 participants (23.2%) developed dementia, of whom 637 developed Alzheimer’s disease. For dementia, the adjusted hazard ratios associated with cumulative benzodiazepine use compared with non-use were 1.25 (95% confidence interval 1.03 to 1.51) for 1-30 TSDDs; 1.31 (1.00 to 1.71) for 31-120 TSDDs; and 1.07 (0.82 to 1.39) for ≥121 TSDDs. Results were similar for Alzheimer’s disease. Higher benzodiazepine use was not associated with more rapid cognitive decline. Conclusion The risk of dementia is slightly higher in people with minimal exposure to benzodiazepines but not with the highest level of exposure. These results do not support a causal association between benzodiazepine use and dementia. BMJ Publishing Group Ltd. 2016-02-02 /pmc/articles/PMC4737849/ /pubmed/26837813 http://dx.doi.org/10.1136/bmj.i90 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/. |
spellingShingle | Research Gray, Shelly L Dublin, Sascha Yu, Onchee Walker, Rod Anderson, Melissa Hubbard, Rebecca A Crane, Paul K Larson, Eric B Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study |
title | Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study |
title_full | Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study |
title_fullStr | Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study |
title_full_unstemmed | Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study |
title_short | Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study |
title_sort | benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737849/ https://www.ncbi.nlm.nih.gov/pubmed/26837813 http://dx.doi.org/10.1136/bmj.i90 |
work_keys_str_mv | AT grayshellyl benzodiazepineuseandriskofincidentdementiaorcognitivedeclineprospectivepopulationbasedstudy AT dublinsascha benzodiazepineuseandriskofincidentdementiaorcognitivedeclineprospectivepopulationbasedstudy AT yuonchee benzodiazepineuseandriskofincidentdementiaorcognitivedeclineprospectivepopulationbasedstudy AT walkerrod benzodiazepineuseandriskofincidentdementiaorcognitivedeclineprospectivepopulationbasedstudy AT andersonmelissa benzodiazepineuseandriskofincidentdementiaorcognitivedeclineprospectivepopulationbasedstudy AT hubbardrebeccaa benzodiazepineuseandriskofincidentdementiaorcognitivedeclineprospectivepopulationbasedstudy AT cranepaulk benzodiazepineuseandriskofincidentdementiaorcognitivedeclineprospectivepopulationbasedstudy AT larsonericb benzodiazepineuseandriskofincidentdementiaorcognitivedeclineprospectivepopulationbasedstudy |